# A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Source: https://onco.cc/trials/nct06378593/  
OnCo record `nct06378593` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of 3HP-2827 in advanced solid tumours, run by 3H (Suzhou) Pharmaceuticals Co., Ltd., now recruiting.

## Summary

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations is a phase 1/2 interventional study registered as NCT06378593 by 3H (Suzhou) Pharmaceuticals Co., Ltd., with 130 participants planned, started 2024-06-17 and due to reach its primary completion in 2028-06-16. Interventions recorded: 3HP-2827.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06378593
- Phase: 1/2
- Setting: An Open-Label, Multi-center Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
- Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd.
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06378593: https://clinicaltrials.gov/study/NCT06378593

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06378593.json